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Objective: To examine the type specific seroprevalence of herpes simplex virus (HSV) types 1 and 2
infections, stratified by age and gender, and associated risk factors for HSV-2 seropositivity in Poland.
Methods: 2257 serum samples of individuals from 15–65 years were randomly selected from serum
banks in four different geographical regions of Poland, including the Zachodnio-pomorskie, Warmińsko-
mazurskie, Lubelskie, and Mazowieckie districts. Type specific serum antibodies to HSV-1 and HSV-2
were detected using HerpeSelect IgG ELISA tests.
Results: Overall prevalences of type specific HSV-1 and HSV-2 serum antibodies were 90.4% and 9.3%,
respectively. Age standardised HSV-2 seroprevalence was higher in women (9.7%) than men (8.8%)
(p = 0.06), and increased notably with age from 4% in 15–24 year olds to 12% in those aged 50–
65 years. HSV-1 seroprevalence was consistently higher than HSV-2 seroprevalence in each specific age
group, ranging from 74.5% in 15–24 year olds to 98.8% in 50–65 year olds. HSV-2 seroprevalence
varied significantly by geographical region, with the highest prevalence in the Zachodnio-pomorskie
district (12%). Significant multivariate risk factors for HSV-2 seropositivity included older age, female
gender, and geographical place of residence.
Conclusion: This large survey found a notably high seroprevalence of HSV-1, even among young female
adolescents 15–19 years of age (80%). HSV-2 seropositivity was under 12% in all age groups surveyed in
Poland, tending to be among the lowest overall HSV-2 seropositivity rates reported thus far in Europe.
H
erpes simplex virus (HSV) infections are among the
most common infections worldwide and cause recur-
rent infections throughout life.1 HSV infects humans of
all ages, and causes a spectrum of diseases, ranging from
asymptomatic infections to neonatal death.2
HSV-1 and HSV-2 type viruses share approximately 50%
nucleotide sequence homology. HSV-1 is usually transmitted
via non-sexual contact and is generally clinically associated
with oro-labial infection, whereas HSV-2 is typically trans-
mitted sexually and infects ano-genital sites.3–5 HSV-1 and
HSV-2 are both capable of infecting ano-genital and oro-
labial sites, and produce clinically indistinguishable lesions.
HSV-1 is an important cause of genital herpes in some
countries.6 Individuals with genital HSV-2 generally have
more frequent recurrences7 8 and viral shedding in the
absence of symptoms than those with genital HSV-1.9
HSV-1 seroprevalence in adults is generally 60% or more in
different areas worldwide and increases with age, reaching a
plateau at around 30 years. HSV-1 is more prevalent than
HSV-2 at any given age group in non-high risk popula-
tions.10 11 HSV-2 seroprevalence varies notably across geogra-
phical regions. In similar aged adults, HSV-2 prevalence is
generally higher in the United States than Europe, and is
higher in women than men.10 In Europe, HSV-2 seropositivity
appears to be higher in northern than southern Europe, and
to be the lowest in Spain and Italy.11
Data from central Europe are sparse. In Poland, no data on
type specific HSV seroprevalence are available. This study
examines HSV-1 and HSV-2 seroprevalence, stratified by age




Serum samples were selected from a serum bank in Poland
established in 2000, with a catchment area of the following
four geographical regions (fig 1): Zachodnio-pomorskie,
Warmińsko-mazurskie, Lubelskie, and Mazowieckie. These
four regions comprise 27.3% of total Polish population.12 The
bank contains residual sera from public health laboratories
that offer comparable services, including diagnostic screening
before surgery (,75%), health screening for new employees
(,15%), diagnostics for infectious diseases other than
sexually transmitted infections and other services, including
visas for international travel (,10%).
A sample of 5 ml of peripheral venous blood was collected,
allowed to clot, and centrifuged at 1000 g for 10 minutes.
Sera were transferred to microtubes of 0.5–1 ml and sent to
the National Institute of Hygiene (NIH) in Warsaw for
storage at 270 C̊. All personal identifiers were removed. The
development of this serum bank was approved by the
institutional review board of the NIH in Warsaw, Poland.
Sampling
A total of 2263 serum samples collected in 2002 were selected
using a stratified sampling design. Samples were randomly
selected in each age and gender group from the Mazowieckie
district (the largest population of all four regions) to obtain
about 100 people per age and gender group, and then from
the other three regions to obtain about 200 people overall per
age and gender group; age distributions were similar for each
region. Additionally, all available samples in 2000 from
Mazowieckie district (n = 222) were tested, and HSV
prevalence results were compared to 838 samples collected
from the same district in 2002.
Laboratory tests
Type specific serum antibodies to HSV-1 and HSV-2 were
detected using HerpeSelect-1 and HerpeSelect-2 IgG ELISAs
Abbreviations: HSV, herpes simplex virus; NIH, National Institute of
Hygiene; STI, sexually transmitted infections
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(Focus Diagnostics). These tests use glycoprotein G antigens:
gG1 from HSV-1 and gG2 from HSV-2 to elicit type specific
antibody responses. Results are reported according to
manufacturer’s instructions. Equivocal samples were retested
using the same test kit. In total, 49 samples were equivocal
and, after retesting, six remained equivocal (three for HSV-1
and three for HSV-2) and were excluded from analyses.
Quality control
The same 170 samples (6.8% of 2485) were blindly retested
with HerpeSelect HSV-1 and HSV-2 ELISA. For both HSV-1
and HSV-2, 165 samples (97.1%) had concordant results.
Initial laboratory results were used for final analyses.
Statistical analysis
The multiple logistic regression model was used to evaluate
risk factors for HSV-2 seropositivity after controlling for age,
gender, HSV-1 serostatus, and region. This regression model
was fitted by starting with a model containing all first and
second order terms and proceeding by backward selection
procedure using SAS statistical software (version 8.2). A
Mantel-Haenszel x2 test was used to determine differences in
HSV-1 and HSV-2 seroprevalence between samples from
2000 and 2002 in the Mazowieckie district.
RESULTS
Type specific serological responses were available in 2002
from sera of 2257 Polish individuals (1218 female, 1039
male) with an overall median age of 34 years. HSV-1 and
HSV-2 seropositivity were 89.8% and 9.1%, respectively.
Antibodies for both HSV-1 and HSV-2 were present in 186
samples (8.2%).
HSV-2 seroprevalence was slightly higher in women (9.6%)
than men (8.7%) (p = 0.06), and varied significantly by
geographical region. The highest HSV-2 prevalence was in
Zachodnio-pomorskie (12%) and the lowest in regions of
Lubelskie (6.5%) and Warmińsko-mazurskie (7%). Overall,
HSV-1 seroprevalence in women (91.5%) was higher than
men (87.9%) (p,0.0001) (table 1). HSV-1 seropositivity was
high across all regions, from ,87% in Mazowieckie and
Zachodnio-pomorskie to 92% in Lubelskie and 94% in
Warminsko-mazurskie.
HSV-2 seroprevalence increased notably with age in both
genders (fig 2A). HSV-2 seropositivity was the lowest in 15–
19 years olds (4.3%), rose steadily to 11.7% in 30–39 year
olds, and reached a plateau over 40 years (varying from 9.3%
to 12.0%). Women had higher HSV-2 seroprevalence than
men at any given age, except 25–29 year olds where
prevalence was comparable at ,8%. HSV-1 was consistently
higher in women than men and lower in younger age groups,
ranging from 74.5% at 15–24 years to 98.8% by 50–65 years
(fig 2B).
Older age was the most significant risk factor for HSV-2
seropositivity (OR = 2.6 for 50–65 year olds versus 15–
24 year olds). Gender was of borderline significance












Total population 1 428 560
Urban population 60%
Warminsko-mazurskie
Total population 1 698 361
Urban population 70%
Zachodnio-pomorskie
Total population 2 199 024
Urban population 47%
Lubelskie
Figure 1 Map of Poland indicating
four districts included in HSV
seroprevalence survey.12
Table 1 Type specific seroprevalence of herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) in Polish women and men,



















Lubelskie 154 39 91.6 7.7 155 42 92.3 5.2
Mazowieckie 554 33 90.3 10.2 281 38 85.4 6.8
Warmińsko-mazurskie 314 35.5 94 8.6 144 46.5 95.1 3.5
Zachodnio-pomorskie 196 28 90.8 10.7 459 28 85.7 12.6
Poland 1218 33 91.5 9.6 1039 35 87.9 8.7
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HSV-1 sero status was not associated with HSV-2
(OR = 0.79). HSV-2 seropositivity was higher in Zachodnio-
pomorskie than Mazowieckie region (OR = 1.7, 95% CI: 1.2 to
2.5) (table 2).
Age adjusted HSV-2 seroprevalence, using the Polish
census population in 2002 as the reference standard
(www.stat.gov.pl), was 9.3% overall (8.8% in men; 9.7% in
women), similar to crude results (9.1% overall; 9.7% in
women, 8.7% in men). After adjusting for age and gender,
HSV-2 seropositivity was significantly higher in Zachodnio-
pomorskie (13.4%) than other regions (5.9%–8.4%) (table 2).
Age adjusted HSV-1 seroprevalence (90.4%) was slightly
higher among women (92.1%) then men (88.5%) (data not
shown).
From 2000 to 2002 in the Mazowieckie region, overall HSV-
1 seropositivity increased slightly from 81.5% to 89.8%
(table 3). In contrast, HSV-2 seropositivity was slightly
higher in 2000 (11.3%) than 2002 (9.5%). Age and gender
adjusted HSV-1 and HSV-2 seroprevalences did not differ
significantly between 2000 and 2002. HSV-1 and HSV-2 rate
ratios between 2000 and 2002 were 1.18 (95% CI: 0.88 to
1.55) and 0.77 (95% CI: 0.53 to 1.11), respectively.
DISCUSSION
This is the first study of HSV-2 and HSV-1 seroprevalence
among women and men in Poland using type specific
serological methods. Age standardised HSV-1 and HSV-2
seroprevalence were 90.4% and 9.3%, respectively, in 2257
samples from serum banks. Age standardised HSV-2 seropo-
sitivity was higher in women (9.7%) than men (8.8%), and
increased notably with age from 4% in 15–19 year olds to
12% in those 40 years or older. HSV-1 seropositivity was
higher than HSV-2 in each age group surveyed and was not
associated with HSV-2 serostatus. Significant multivariate
risk factors for HSV-2 included older age, female gender, and
geographical region of residence.
Reliability of these results is based on a large sample size
and standardised laboratory procedures for type specific HSV
tests. This is the largest study of HSV-2 in Poland to date
(n = .2000 sera), including both genders from four regions.
ELISAs for type specific HSV-1 and HSV-2 serum antibody
detection in order to determine cumulative lifetime exposure
to infection. Previous validation studies show high sensitivity
and specificity for HSV-1 and HSV-2 Focus Diagnostics
ELISAs when compared to the gold standard HSV western
blot.13 14 Further, a high percentage agreement (97%) for
reproducibility of HSV serological results was found. One
limitation, however, is that determination of HSV-2 seropre-
valence may underestimate the total burden of genital herpes
in areas where a notable proportion of genital herpes is
caused by HSV-1.5
This study is based on a large serum bank from Polish
regional public health laboratories that form a countrywide
network offering similar services in all regions. Catchment
areas are large, including a wide reference population
referred for surgery and other diagnostic testing. Given that
a notable proportion of individuals are seen for routine pre-
surgery screening, it is plausible that participants are not
likely to differ significantly from a population based sample
of similarly aged women and men in these four regions.
However, serum bank donors in Poland may differ from the
general Polish population, and thus study results may not be
representative of the Polish population at large.
HSV-2 seroprevalence in this Polish population (median
age of 34) (9.1%) is comparable to similarly aged women
from population based surveys in Barcelona, Spain (11%)15






















































Figure 2 HSV-2 (A) and HSV-1 (B) seroprevalence in Poland by age in
2002, stratified by gender.





(%) OR (95% CI)
Age group (years) 15–24 630 6.0* 1
25–49 1081 9.8* 1.9 (1.3 to 2.7)
50–65 546 11.5* 2.6 (1.7 to 4.1)
Overall 2257 9.3` p for trend = 0.004
Sex Male 1039 9.8 1
Female 1218 9.7 1.4 (0.99 to 1.8)
HSV-1 serostatus Negative 227 9.8` 1
Positive 2030 10.7` 0.79 (0.48 to 1.3)
Region in Poland Mazowieckie 835 8.3` 1
Lubelskie 309 6.6` 0.69 (0.41 to 1.2)
Warminsko-mazurskie 458 5.9` 0.72 (0.47 to 1.1)
Zachodnio-pomorskie 655 13.4` 1.7 (1.2 to 2.5)
OR, multivariate odds ratio adjusted for age, gender, HSV-1 serostatus, and region.
*Gender adjusted HSV-2 seroprevalence; age group adjusted HSV-2 seroprevalence; `age group and gender
adjusted HSV-2 seroprevalence; CI: confidence interval, 1, reference.
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population based samples from Spain (2.7–,5%),17 18 Czech
Republic (6%),19 and Central Italy (4.8%).20 HSV-2 seroposi-
tivity overall in Poland was lower, however, than in women
from northern and eastern Europe,10 19 such as a population
based sample in Germany (14%);19 two studies of women in
Norway(25–28%)21 22; Swedish studies of pregnant women
(,34%)23 24; and population based studies19 in Finland (13%),
the Netherlands (9%), Bulgaria (24%), and Belgium (11%).
Comparisons of age specific HSV-2 seroprevalence between
studies, however, require caution given differences in type
specific assays and in populations surveyed.
Few surveys have included both genders to compare age
specific HSV-2 seroprevalence using identical type specific
HSV-1 and HSV-2 laboratory methods. HSV seroepidemiolo-
gical studies in Poland have generally been conducted using
non-specific serological tests that do not effectively distin-
guish HSV-1 and HSV-2 antibody responses, by using a
complement fixation test25 or laboratory specific, non-
standardised HSV-1 ELISA.26 In our study, Polish women
had a higher risk of HSV-2 seropositivity than men
(OR = 1.4). These results are similar to US and European
studies27–29 and provide consistent evidence that women are
probably at a higher risk of HSV-2 acquisition than men.
A higher HSV-2 seroprevalence was found among women
and men from Zachodnio-pomorskie than the other three
Polish regions, and the reason for this is unclear. Differences
in HSV-2 seropositivity may be the result of regional
differences in sexual norms or population based seropreva-
lence. Higher HSV-2 seroprevalence in Zachodnio-pomorskie
is consistent with a higher incidence of non-gonococcal
urethritis in this district than the three other regions
(www.pzh.gov.pl/epimeld). However, reported rates of other
sexually transmitted infections (STIs) in 2002 have been
higher in the other regions than in Zachodnio-pomorskie
(that is, a higher prevalence of syphilis was reported in
Warminsko-mazurskie; a higher prevalence gonorrhoea in
Mazowieckie). Differences in reported STI rates across
regions might represent true differences in STI prevalence
or regional differences in diagnosis or reporting patterns.
HSV-2 seropositivity may be a useful indicator of future HIV
population risk30 or be an actual risk factor for HIV
transmission.31 Thus, these data indicate that future public
health efforts may need to consider regional approaches to
STI/HIV prevention in Poland.
Consistent with previous studies, HSV-1 seropositivity level
in four areas in Poland (,89%) was more prevalent than
HSV-2. HSV-1 burden in Poland is similar to that of similarly
aged men and women (,34 years) in Germany (82% in
blood donors),32 Bulgaria (84% in a population based
study),19 Spain (84% in a population based study),17 the
Czech Republic (81% in a population based study),19 and
central Italy (93% in 30 year old health personnel).33 HSV-1
seropositivity in Poland is slightly lower than a similarly aged
national sample from England and Wales (,69%) and than
population based studies19 in the Netherlands (57%), Belgium
(67%), and Finland (52%).
In this study, HSV-1 seropositivity was not associated HSV-
2 serostatus. It has been hypothesised that HSV-1 seroposi-
tive individuals may have a lower acquisition of HSV-2
infection because of cross protection of HSV-1 against HSV-2,
yet results from two HSV-2 prophylactic clinical trials have
inconsistent results.34 35 Our ability to address this issue is
limited, however, because of this study’s cross sectional
design and lack of information on other potential sexual
behavioural confounders.
Data on HSV-1 seroprevalence in female adolescents/young
women (aged 15–24 years) have important implications
for the future introduction of an HSV-2 prophylactic vaccine
because this vaccine will probably only be effective in
dually HSV-1/HSV-2 seronegative women.34 HSV-1 seropre-
valence in Polish females aged 15 and 24 was 83.4%,
suggesting that vaccination earlier in life than adolescence
could maximise potential vaccine benefits. These data are
consistent with European studies that found a range of 60%
to 90% of HSV-1 in females aged ,15–24 years from
Germany (,60%),32 19 Belgium(,65%),19 Spain (72%),17
Finland (72%),36 the Czech Republic(,75%),19 central Italy
(85%),33 Bulgaria (,85%),19 and Slovenia (85%),19 but are
slightly higher than in similarly aged women in the
Netherlands (,40%),19 Wales and England (,40–50%),19 37
and Finland (40%).19 In female adolescents aged 15 years in
Poland, the prevalence of dual HSV-1/HSV-2 seronegativity
was 18.9% (24/127)—13.8% in Zachodnio-pomorskie, 13.9%
in Warminsko-mazurskie, 29% in Lubelskie, and 22% in
Mazowieckie.
Our results indicate a relatively low age standardised
prevalence of HSV-2 seropositivity in serum bank specimens
from women and men aged 15–65 years of age in four regions
of Poland. Overall age standardised HSV-2 seroprevalence
(9.3%) in Poland appears to be similar to other ‘‘low’’ HSV-2
prevalence areas within Europe, and was lower than many
other European countries, particularly in northern Europe.
Age standardised HSV-1 seropositivity among serum samples
in Poland (90.4%) was consistent with other European
surveys. The HSV-2 prophylactic vaccine currently in phase
III trials is planned to target female adolescents 15 years of
age. Given that ,20% of young women in Poland would be
HSV-1/HSV-2 seronegative and thus eligible for vaccination,
future strategies may benefit from vaccinating females
younger than 15 years of age, while considering the length
of proved HSV-2 vaccine efficacy.
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Females overall 140 83.6 12.9 557 90.3 10.2
Males overall 82 78.1 8.5 281 85.4 6.8
Total
15–24 99 67.7 11.1 208 78.8 6
25–49 97 90.7 10.3 409 91.9 9.8
50+ 26 100 15.4 201 98.5 11.5
Overall 222 81.5 11.3 838 89.8 9.5
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www.stijournal.com
CONTRIBUTORS
JMP and BL initiated the project, and BL is the study guarantor; JS
and AT were responsible for performed tests, internal quality control,
data collection, and analysis; JSS and MR provided methodological
and statistical part of the project and were responsible for
epidemiological analysis of data; all contributors were involved in
paper preparation.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
J S Smith, University of North Carolina, Chapel Hill, NC, USA
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Key messages
N HSV-2 seropositivity was under 12% in all age groups
surveyed from blood banks in four regions of Poland,
tending to be among the lowest reported thus far in
Europe
N HSV-1 seroprevalence was high in Poland, even
among young female adolescents aged 15–19 years
(80%)
N HSV-2 serostatus was associated with older age,
female gender, and geographical place of residence,
but not with HSV-1 serostatus
N In Poland, approximately 20% of young women aged
15 years would be potentially eligible for vaccination
with a prophylactic HSV vaccine targeted at HSV-1/
HSV-2 dually negative young female adolescents
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